CClinicalTrials.gg
Not yet recruitingNCT07467148Updated Mar 12, 2026

Placental Thickness -To-Fetal Weight Ratio as a Predictor of Adverse Pregnancy Outcome

An observational study in Placental Thickness and PLACENTA VOLUME, sponsored by Radia Atef Elzokm. Not yet recruiting. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Radia Atef Elzokm · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
20 Years to 45 Years
Sex
Female
01

Study summary

The aim of this study is to evaluate the placental thickness-to-fetal weight ratio as a predictor of adverse pregnancy outcomes.

Read the detailed description

The placenta is a vital organ that ensures normal fetal growth and development throughout pregnancy by mediating the exchange of oxygen, nutrients, waste products, and essential hormones between the mother and the fetus (1). Any structural or functional abnormality of the placenta can adversely affect fetal growth and pregnancy outcome, highlighting the importance of placental assessment in antenatal care (2).

Adverse pregnancy outcomes, including intrauterine growth restriction (IUGR), preterm birth, low birth weight, preeclampsia, fetal distress, and perinatal mortality, remain major contributors to maternal and neonatal morbidity and mortality worldwide. Early identification of high-risk pregnancies allows timely interventions, closer surveillance, and improved perinatal outcomes (3). However, advances in ultrasonography and antenatal care, reliable, non-invasive, and easily measurable predictors of adverse outcomes are still limited (4).

Ultrasonographic evaluation of placental morphology has emerged as a practical, non-invasive, and widely accessible method to assess placental health. Among the various parameters, placental thickness reflects placental growth, maturation, and potentially its functional capacity, correlating with gestational age and fetal weight in normal pregnancies. Abnormal placental thickness either decreased or increased has been associated with maternal and fetal pathological conditions (5).

A thin placenta is frequently linked to preeclampsia, IUGR, and chorioamnionitis, whereas a thick placenta defined as more than 3 cm before 20 weeks of gestation and greater than 5 cm at term is observed in Rh-negative pregnancies, gestational diabetes mellitus, and intrauterine infections, particularly primary maternal cytomegalovirus infection (6). Placentomegaly may also be associated with fetal anemia or hromosomal abnormalities such as triploidy, and may result from inflammation, edema, or compensatory hypertrophy secondary to placental insufficiency (7).

Maternal disorders often affect both the fetus and the placenta, making abnormal placental growth a potential marker for impaired fetal growth and adverse neonatal outcomes. Nevertheless, the predictive value of placental thickness alone remains uncertain (8).

Given its simplicity, reproducibility, and cost-effectiveness, ultrasonographic measurement of placental thickness and particularly the placental thickness-to-fetal weight ratio may provide a valuable tool for early detection of high-risk pregnancies. This could allow obstetricians to implement timely interventions, optimize delivery planning, and improve maternal and neonatal outcomes (9). Therefore, this study aims to evaluate the placental thickness-to-fetal weight ratio as a predictor of adverse pregnancy outcomes.

02

Conditions studied

  • Placental Thickness
  • PLACENTA VOLUME
03

In context

Lead sponsor

This is the only study on the registry with Radia Atef Elzokm as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospital

Inclusion criteria

  • a. Inclusion criteria: Singleton pregnancy. Gestational age between 28-38 weeks. Mothers willing to participate and provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • Multiple pregnancies (twins, triplets,etc.) Known congenital fetal anomalies Maternal chronic medical conditions affecting fetal growth (e.g pre-existing diabetes, hypertension, renal disease) Intrauterine fetal demise Inability or refusal to provide informed consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The rate of occurrence of adverse pregnancy outcomes, including IUGR, preterm birth, low birth weight, fetal distress, NICU admission, or perinatal mortality

    Correlation of placental thickness-to-fetal weight ratio with individual adverse pregnancy outcomes

    Time frame: From aug 2026 to aug 2029

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • 1.Burton GJ and Jauniaux E. The human placenta: new perspectives on its formation and function during early pregnancy. Proc Biol Sci. 2023;290(13):202-8. 2. Aye IL, Tong S, Charnock-Jones DS and Smith GC. The human placenta and its role in reproductive outcomes revisited. Physiol Rev. 2025;12(2):25-30. 3. Patel SY, Akileswaran C and Basu S. Early detection of high risk pregnancies using clinical and social data to improve health outcomes. npj Digit Public Health. 2026;10(1):3-10. 4. Wang X, Xiao F and Li J. Intrapartum ultrasound monitoring in second-stage Labor: Impact on delivery outcomes. J Radiat Res Appl Sci. 2025;18(4):105-10. 5. Farahbod F, Zarean E, Khanjani S, Moezzi M, Mohammadizadeh F and Shabanian S. Relationship between placental thickness, grading, and heterogeneity in fetal growth restriction in the third trimester of pregnancy by ultrasonography and pathology tests and their relationship with estimated fetal weight and neonatal outcome. Immunopathol Persa. 2023;10(2):39471-6. 6. Li H, Cheng W, Wen J, Peng J, Wu S, Zhao Y, et al. Clinical analysis of prophylactic uterine artery embolization combined with double balloon catheter for second-trimester pregnancy termination in cases of complete placenta previa: A retrospective study. Medicine. 2023;102(47):362-9. 7. Redline RW, Roberts DJ, Parast MM, Ernst LM, Morgan TK, Greene MF, et al. Placental pathology is necessary to understand common pregnancy complications and achieve an improved taxonomy of obstetrical disease. Am J Obstet Gynecol. 2023;228(2):187-202. 8. Manna C, Lacconi V, Rizzo G, De Lorenzo A and Massimiani M. Placental dysfunction in assisted reproductive pregnancies: perinatal, neonatal and adult life outcomes. Int J Mol Sci. 2022;23(2):659-62. 9. Chow LY, Williams EE, Patel D-S and Battersby C. Perinatal optimisation: the role of the multi-disciplinary team. OB-GYN 2025;22(1):25-30. 10. Lwanga SK, Lemeshow S. Sample size determination in health studies: a practical manual. Geneva: World H

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07467148
Lead sponsor
Radia Atef Elzokm
Responsible party
Radia Atef Elzokm (Assiut university, Assiut University) — Sponsor-investigator
First posted
Mar 12, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Mar 12, 2026

Study contacts

Radia Atef Elzokm, Resident doctor
Contact
saraatef52222@gmail.com
01202170497
Ahmed Mohamed Abbas, Professor
Contact
Aahmedabbas@aun.edu.eg
01003385183

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion